. Effect of NO-Aspirins on the viability and proliferation of nonsmall cell lung cancer (NSCLC) cells. H1299 cells were exposed to aspirin, NCX4016, and NCX4040 in 2-fold dilution series. Cell viability (by MTT reduction) and proliferation (by BrdU uptake) were measured at 96 and 24 h, respectively. A. Effects of aspirin (ASA), NCX4016, and NCX4040 on H1299 cell viability. B. Effects of aspirin (ASA), NCX4016, and NCX4040 on proliferation of H1299 cells. Graphs show representative graphs of three experiments performed in triplicate.
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. Effect of NO-Aspirins on the viability and proliferation of nonsmall cell lung cancer (NSCLC) cells. H1299 cells were exposed to aspirin, NCX4016, and NCX4040 in 2-fold dilution series. Cell viability (by MTT reduction) and proliferation (by BrdU uptake) were measured at 96 and 24 h, respectively. A. Effects of aspirin (ASA), NCX4016, and NCX4040 on H1299 cell viability. B. Effects of aspirin (ASA), NCX4016, and NCX4040 on proliferation of H1299 cells. Graphs show representative graphs of three experiments performed in triplicate. Figure S2 . Concentration-response curves of aspirin, NO-Aspirins, and erlotinib on viability of non-small cell lung cancer (NSCLC) cells. The effects of aspirin, NCX4016, NCX4040, and erlotinib on cell viability were measured by MTT assay. Three NSCLC cell lines were used: A549 (left column), H1299 (middle column), and H1975 (right column). Cells were exposed to different drugs in 2-fold dilution series for 96 h. Data were loaded in COMBENEFIT software to plot concentration-response curves and combination studies (Figure 4) . "Abs EC50" indicates the concentration that reduced cell viability by 50%, normalized using control data. Figure S3 . Effect of NO-Aspirins combined with erlotinib on the viability of non-small cell lung cancer (NSCLC) cells. The effects of combinations of aspirin, NCX4016, and NCX4040 with erlotinib on cell viability were measured by MTT assay, using three NSCLC cell lines: A549 (upper panels), H1299 (middle panels), and H1975 (lower panels). Cells were exposed to the different drugs for 96 h. For drug combinations, two-fold dilution series, comprising six concentrations, were mixed in every possible combination. Effects matrices were plotted using COMBENEFIT software, which builds an XYZ model of the combination, using the effect of each drug alone, and the Loewe's model of drug additivity. Differences between the theoretical combinations and empirical data are represented by a number generated for every combination point. Positive numbers represent synergistic combinations, while negative numbers indicate antagonistic interactions. The color code shows combination points that are significantly different from the theoretical model, calculated by t-test. *p < 0.05. Each graph represents the mean ± standard deviation of three independent experiments, each performed in duplicate.

